Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MiMedx Group, Inc (MDXG : NSDQ)
 
 • Company Description   
MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. `Innovations in Regenerative Biomaterials` is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.

Number of Employees: 808

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.57 Daily Weekly Monthly
20 Day Moving Average: 913,281 shares
Shares Outstanding: 145.76 (millions)
Market Capitalization: $666.12 (millions)
Beta: 1.43
52 Week High: $7.97
52 Week Low: $3.03
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 7.03% 7.50%
12 Week 24.18% 21.54%
Year To Date -32.50% -40.13%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1775 W OAK COMMONS COURT NE
-
MARIETTA,GA 30062
USA		 ph: 770-651-9100
fax: 678-384-6741		 investorrelations@mimedx.com http://www.mimedx.com
 
 • General Corporate Information   
Officers
Joseph H. Capper - Chief Executive Officer and Director
M. Kathleen Behrens - Chair of the Board
Doug Rice - Chief Financial Officer
James L. Bierman - Director
William A. Hawkins III - Director

Peer Information
MiMedx Group, Inc (CORR.)
MiMedx Group, Inc (RSPI)
MiMedx Group, Inc (CGXP)
MiMedx Group, Inc (BGEN)
MiMedx Group, Inc (GTBP)
MiMedx Group, Inc (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 602496101
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/04/26
Share - Related Items
Shares Outstanding: 145.76
Most Recent Split Date: (:1)
Beta: 1.43
Market Capitalization: $666.12 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.10 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/04/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 24.05
PEG Ratio: -
Price Ratios
Price/Book: 3.08
Price/Cash Flow: 8.25
Price / Sales: 1.88
EPS Growth
vs. Year Ago Period: -150.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -34.73%
vs. Previous Quarter: 9.10%
ROE
06/30/26 - 12.09
03/31/26 - 21.03
12/31/25 - 29.37
ROA
06/30/26 - 9.22
03/31/26 - 15.92
12/31/25 - 21.97
Current Ratio
06/30/26 - 5.33
03/31/26 - 5.39
12/31/25 - 4.32
Quick Ratio
06/30/26 - 4.79
03/31/26 - 4.81
12/31/25 - 3.92
Operating Margin
06/30/26 - 8.13
03/31/26 - 12.89
12/31/25 - 16.05
Net Margin
06/30/26 - 1.76
03/31/26 - 7.88
12/31/25 - 11.60
Pre-Tax Margin
06/30/26 - 3.25
03/31/26 - 10.87
12/31/25 - 15.83
Book Value
06/30/26 - 1.48
03/31/26 - 1.63
12/31/25 - 1.73
Inventory Turnover
06/30/26 - 3.04
03/31/26 - 2.87
12/31/25 - 2.90
Debt-to-Equity
06/30/26 - 0.07
03/31/26 - 0.07
12/31/25 - 0.06
Debt-to-Capital
06/30/26 - 6.78
03/31/26 - 6.21
12/31/25 - 6.03
 

Powered by Zacks Investment Research ©